Shares of Corbus Pharmaceuticals Holdings Inc. CRBP rose 6.15% to $8.28 Thursday, on what proved to be an all-around dismal ...

This was the stock's second consecutive day of losses.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) announced that data from its US and UK first-in-human dose escalation ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cybin (CYBN – Research Report) and Corbus ...

Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report) today and set a price ...

Corbus Pharmaceuticals has posted the first Western clinical data on its would-be rival to Pfizer’s Padcev. The overall ...

Analysts at HC Wainwright issued their FY2029 earnings estimates for shares of Corbus Pharmaceuticals in a note issued to investors on Monday, February 10th. HC Wainwright analyst A. Maldonado expects ...

Corbus Pharmaceuticals announced results from its first-in-human dose escalation study of CRB-701, presented at the ASCO GU 2025 conference. This Phase 1 study assessed the efficacy and safety of ...

Participants in HNSCC, cervical, and mUC tumors are being randomized to the 2.7 mg/kg and 3.6 mg/kg cohorts. Price Action: CRBP stock is down 8.23% at $8.70 at the last check on Friday.